D.A. Davidson & CO. grew its stake in Adaptimmune Therapeutics PLC (NASDAQ:ADAP) by 51.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,511 shares of the biotechnology company’s stock after purchasing an additional 18,500 shares during the quarter. D.A. Davidson & CO. owned approximately 0.08% of Adaptimmune Therapeutics worth $446,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Renaissance Technologies LLC increased its position in shares of Adaptimmune Therapeutics by 75.4% during the first quarter. Renaissance Technologies LLC now owns 780,800 shares of the biotechnology company’s stock valued at $4,302,000 after acquiring an additional 335,700 shares during the last quarter. KCG Holdings Inc. purchased a new stake in shares of Adaptimmune Therapeutics during the first quarter valued at approximately $133,000. Essex Investment Management Co. LLC increased its position in shares of Adaptimmune Therapeutics by 371.0% during the second quarter. Essex Investment Management Co. LLC now owns 192,045 shares of the biotechnology company’s stock valued at $862,000 after acquiring an additional 151,273 shares during the last quarter. Alps Advisors Inc. increased its position in shares of Adaptimmune Therapeutics by 4.9% during the second quarter. Alps Advisors Inc. now owns 63,892 shares of the biotechnology company’s stock valued at $287,000 after acquiring an additional 2,996 shares during the last quarter. Finally, Baillie Gifford & Co. increased its position in shares of Adaptimmune Therapeutics by 43.7% during the second quarter. Baillie Gifford & Co. now owns 1,323,308 shares of the biotechnology company’s stock valued at $5,941,000 after acquiring an additional 402,324 shares during the last quarter. Institutional investors own 71.92% of the company’s stock.

Shares of Adaptimmune Therapeutics PLC (ADAP) opened at $8.23 on Wednesday. Adaptimmune Therapeutics PLC has a 52-week low of $3.76 and a 52-week high of $9.29.

A number of analysts recently commented on ADAP shares. SunTrust Banks reaffirmed a “buy” rating and set a $10.00 price target on shares of Adaptimmune Therapeutics in a research report on Thursday, October 12th. BidaskClub raised Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. Zacks Investment Research downgraded Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. TheStreet raised Adaptimmune Therapeutics from a “d” rating to a “c” rating in a research report on Thursday, November 2nd. Finally, Leerink Swann reissued an “outperform” rating and issued a $15.00 target price on shares of Adaptimmune Therapeutics in a research report on Friday, September 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $11.58.

TRADEMARK VIOLATION NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.watchlistnews.com/d-a-davidson-co-buys-18500-shares-of-adaptimmune-therapeutics-plc-adap/1732122.html.

Adaptimmune Therapeutics Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Want to see what other hedge funds are holding ADAP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptimmune Therapeutics PLC (NASDAQ:ADAP).

Institutional Ownership by Quarter for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.